Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Date

Click to order products ascending

Display 15 Products per page

Market Spotlight: Hypogonadism

$1,318.00

The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
November 18, 2022
Find out more
Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)
Read More
The diagnosis of non-alcoholic fatty liver disease (NAFLD) requires evidence of hepatic steatosis and the lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is a more advanced form of NAFLD where there is liver inflammation with hepatocyte injury, which can lead to hepatic fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage. Detection of fibrosis is important as it is linked to worse outcomes for patients.
November 18, 2022
Find out more
Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

$1,318.00

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 18, 2022
Find out more
Disease Analysis: Diabetic Nephropathy
Read More
Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.
November 21, 2022
Find out more
Disease Analysis: Meningococcal Vaccines
Read More
Meningococcal meningitis is caused by the bacteria Neisseria meningitidis, which causes a serious infection to the lining surrounding the brain and spinal cord. In all, 12 known serogroups of Neisseria meningitidis have been identified, six of which (A, B, C, W, X, and Y) can cause epidemics. The Centers for Disease Control and Prevention (CDC) has reported around 1 in 10 people are asymptomatic carriers of the bacteria.
November 22, 2022
Find out more
Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

$1,318.00

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 24, 2022
Find out more
Market Spotlight: Biliary Tract Cancer

$1,318.00

This Market Spotlight report covers the Biliary Tract Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 24, 2022
Find out more
Disease Analysis: HIV Treatment
Read More
The HIV treatment market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand through to 2025, driven primarily by increases in disease prevalence and continued uptake of Gilead’s Biktarvy and ViiV Healthcare’s portfolio of two-drug regimens. However, a plethora of products undergoing patent expiry across the forecast period will tip the market into decline from 2026.
November 29, 2022
Find out more
Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)
Read More
The “ABCD” GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value. Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist Spiriva in the treatment of more severe COPD.
November 29, 2022
Find out more
Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)
Read More
Despite Truvada’s and Descovy’s commercial success, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as due to Gilead’s marketing efforts. The US has the highest rate of uptake (estimated at 22% of at-risk individuals in 2020) and generates the majority of global PrEP revenues.
November 30, 2022
Find out more
Disease Analysis: Bipolar Disorder
Read More
BD is a multifactorial psychiatric mood disorder influenced by social, environmental, and genetic risk factors underlying its etiology. The disorder is characterized by fluctuating mood states, such as mania and depression, interspersed with periods of wellbeing over days and weeks. BD describes a range of disease subtypes, including BD type I, BD type II, and cyclothymia.
November 30, 2022
Find out more
Disease Analysis: Renal Cell Carcinoma (RCC)
Read More
Sutent is set to lose ground due to both newer, more effective treatments and imminent biosimilar erosion. Previously the SOC across many treatment settings, the pivotal trials of several newer therapies, which include checkpoint inhibitors Keytruda, Opdivo, and Bavencio, and the RTK inhibitor Cabometyx, have demonstrated significant clinical benefit over Sutent in the first-line setting. Keytruda and Cabometyx have also demonstrated benefit over Sutent in subsequent-line settings.
December 1, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL)
Read More
The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.
December 1, 2022
Find out more
Disease Analysis: Cystic Fibrosis
Read More
Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications.
December 2, 2022
Find out more
Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
December 6, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *